Phase I Safety and Pharmacokinetic Study of CT-011, a Humanized Antibody Interacting with PD-1, in Patients with Advanced Hematologic Malignancies

By R. Berger, R. Rotem‐Yehudar, G. Slama, S. Landes, A. Kneller, M. Leiba, M. Koren-Michowitz, A. Shimoni, A. Nagler. Clinical Cancer Research, 2008

687 citations recorded by the source corpus.

Subfields: Immunology, Oncology, Radiology, Nuclear Medicine and Imaging

View Paper: https://www.semanticscholar.org/paper/268b6be38435e2faa37ab99027e59441a6840b0c

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

In Oncology

Citations in the corpus

Prostate cancer and inflammation: the evidence (2012, background): “Very promising results are arising from clinical trials based on treatment strategies utilizing monoclonal antibodies for PD-1 blockade for multiple forms of advanced malignancies.(94,95) Anti-PD-1 treatment strategies may also prove to be beneficial in prostate cancer therapeutic strategies, as pro”
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma (2014, neutral): “Decreased lymphocyte count 2 (9) 1 (4)”
PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome (2017, background): “…antibody, has been tested in various hematologic malignancies, showing potential clinical impact in patients with non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, Hodgkin’s lymphoma, multiple myeloma, and acute myeloid leukemia (Berger et al., 2008; Atkins et al., 2014; Westin et al., 2014).”
PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors (2010, background): “Human studies of αPD-1 and αPD-L1 antibodies are at a much earlier stage yet suggest that these agents may be efficacious while engendering fewer autoimmune complications (27).”
Inhibiting DNA methylation causes an interferon response in cancer via dsRNA including endogenous retroviruses (2015, positive): “…important implications for one of the most exciting new developments in cancer treatment, immune checkpoint therapy (Brahmer et al., 2010, 2012; Berger et al., 2008; Leach et al., 1996; Topalian et al., 2015; Hodi et al., 2010; Weber et al., 2015) and for underlying mechanisms inherent to both…”
Targeting FTO suppresses cancer stem cell maintenance and immune evasion (2020, neutral): “, 2012), but demonstrated only limited effects in AML (Berger et al., 2008).”
Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity (2012, positive): “CT-011, a humanized mAb, was first tested in a single-dose regimen in 17 patients with advanced hematologic malignancies [41], and was generally well-tolerated.”